Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Merck
Citi
Healthtrust
Fish and Richardson
Johnson and Johnson
Boehringer Ingelheim
Covington
McKesson

Generated: August 15, 2018

DrugPatentWatch Database Preview

TORISEL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Torisel patents expire, and what generic alternatives are available?

Torisel is a drug marketed by Pf Prism Cv and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-three patent family members in thirty-eight countries.

The generic ingredient in TORISEL is temsirolimus. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the temsirolimus profile page.

Drug patent expirations by year for TORISEL
Generic Entry Opportunity Date for TORISEL
Generic Entry Date for TORISEL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for TORISEL
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0;{4,9}]hexatriaconta-16,24,26,28-tetraen-12
1034922-90-1
162635-04-3
343261-52-9
42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
42-[3-Hydroxy-2-methylpropanoate
624KN6GM2T
635T043
AB01274736_02
AB01274736-01
AC-8758
AC1L3WME
AKOS025142069
AKOS025402386
AM84554
AN-5331
AOB87306
AS-11427
BC677694
BDBM50343413
C15182
C56H87NO16
CAS-162635-04-3
CBPNZQVSJQDFBE-FUXHJELOSA-N
Cci 779
CCI-779
CCI779
CHEBI:79699
CHEMBL1201182
CS-0129
CTK8E8547
D06068
D0ES1Q
DB06287
DSSTox_CID_20945
DSSTox_GSID_40945
DSSTox_RID_79605
DTXSID2040945
EBD30128
EX-A957
GTPL5892
HSDB 7931
HY-50910
J-009958
J-524319
LS-186555
LS-187004
LS-187783
MFCD00934421
MolPort-003-850-408
MolPort-042-665-740
MolPort-044-561-110
NCGC00167518-01
NCGC00167518-02
NSC-683864
NSC683864
Rapamycin 42-(2,2-bis(hydroxymethyl)propionate)
Rapamycin 42-[2,2-bis(hydroxymethyl)propionate]
Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate
Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]
Rapamycin 42-[3-hydroxy-2(hydroxymethyl)-2-methylpropanoate]
Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)
RL02091
RT-015903
s1044
SCHEMBL16234472
SCHEMBL16848395
SCHEMBL18792
SR-01000898799
SR-01000898799-3
Temserolimus
Temsirolimus
Temsirolimus - Torisel
Temsirolimus (CCI-779, NSC 683864)
Temsirolimus (JAN/USAN/INN)
Temsirolimus [USAN:INN:BAN:JAN]
Temsirolimus [USAN]
Temsirolimus, >=98% (HPLC)
Temsirolimus(CCI-779)
Temsirolimus|162635-04-3|CCI-779|CCI 779|CCI779
Temsorolimus
Torisel (TM)
Torisel (TN)
Tox21_112515
UNII-624KN6GM2T
WAY-130,779
WAY-CCI 779

US Patents and Regulatory Information for TORISEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for TORISEL
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 25 mg/mL, 1.8 mL vial ➤ Subscribe ➤ Try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for TORISEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008009,C0763039 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUSUM; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
438 Luxembourg ➤ Try a Free Trial 91438, EXPIRES: 20200414
00348 Netherlands ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Baxter
AstraZeneca
Medtronic
Federal Trade Commission
Chubb
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.